TET1 and cholangiocarcinoma: For instance, olaparib, a clinically approved poly ADP ribose polymerase (PARP) inhibitor, has been demonstrated to induce 5hmC labeling loss, thereby inhibiting the proliferation of T‐ALL leukemia cells.[36] The role of TET1 in CCA has been the subject of several studies.